Nitisinone Dipharma 2 mg hard caps. Belgien - engelska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

nitisinone dipharma 2 mg hard caps.

dipharma arzneimittel gmbh - nitisinone 2 mg - capsule, hard - 2 mg - nitisinone 2 mg - nitisinone

Nitisinone Dipharma 20 mg hard caps. Belgien - engelska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

nitisinone dipharma 20 mg hard caps.

dipharma arzneimittel gmbh - nitisinone 20 mg - capsule, hard - 20 mg - nitisinone 20 mg - nitisinone

ORFADIN nitisinone 4 mg/mL oral suspension bottle Australien - engelska - Department of Health (Therapeutic Goods Administration)

orfadin nitisinone 4 mg/ml oral suspension bottle

a menarini australia pty ltd - nitisinone, quantity: 4 mg - oral liquid, suspension - excipient ingredients: hypromellose; glycerol; polysorbate 80; sodium benzoate; citric acid monohydrate; sodium citrate; purified water; flavour - orfadin (nitisinone) is indicated for the treatment of patients with hereditary tyrosinaemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.

ORFADIN nitisinone 20 mg capsule bottle Australien - engelska - Department of Health (Therapeutic Goods Administration)

orfadin nitisinone 20 mg capsule bottle

a menarini australia pty ltd - nitisinone, quantity: 20 mg - capsule, hard - excipient ingredients: pregelatinised maize starch; titanium dioxide; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; ethanol absolute; iron oxide black; potassium hydroxide - orfadin (nitisinone) is indicated for the treatment of patients with hereditary tyrosinaemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.

HIGHLIGHTS OF PRESCRIBING INFORMATION USA - engelska - NLM (National Library of Medicine)

highlights of prescribing information

novitium pharma llc - nitisinone (unii: k5bn214699) (nitisinone - unii:k5bn214699) - nitisinone capsules are indicated for the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine. none. risk summary limited available data with nitisinone use in pregnant women are not sufficient to determine a drug-associated risk of adverse developmental outcomes. animal reproduction studies have been conducted for nitisinone. in these studies, nitisinone was administered to mice and rabbits during organogenesis with oral doses of nitisinone up to 20 and 8 times respectively, the recommended initial dose of 1 mg/kg/day. in mice, nitisinone caused incomplete skeletal ossification of fetal bones and decreased pup survival at doses 0.4 times the recommended initial dose, and increased gestational length at doses 4 times the recommended initial dose. in rabbits, nitisinone caused maternal toxicity and incomplete skeletal ossification of fetal bones at doses 1.6 times the recommended initial dose [see data]. the b

NITISINONE DIPHARMA 10 MG Israel - engelska - Ministry of Health

nitisinone dipharma 10 mg

mbi pharma ltd., israel - nitisinone - hard capsule - nitisinone 10 mg - nitisinone - treatment of patients with confirmed diagnosis of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine

NITISINONE DIPHARMA 5 MG Israel - engelska - Ministry of Health

nitisinone dipharma 5 mg

mbi pharma ltd., israel - nitisinone - hard capsule - nitisinone 5 mg - nitisinone - treatment of patients with confirmed diagnosis of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine

ORFADIN 2 MG HARD CAPSULES Israel - engelska - Ministry of Health

orfadin 2 mg hard capsules

megapharm ltd - nitisinone - hard capsule - nitisinone 2 mg - nitisinone - nitisinone - treatment of patients with confirmed diagnosis of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine05/06/2018 בקשה לשינוי משטר מינון once daily

ORFADIN 5 MG HARD CAPSULES Israel - engelska - Ministry of Health

orfadin 5 mg hard capsules

megapharm ltd - nitisinone - hard capsule - nitisinone 5 mg - nitisinone - nitisinone - treatment of patients with confirmed diagnosis of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine05/06/2018 בקשה לשינוי משטר מינון once daily

ORFADIN 10 MG HARD CAPSULES Israel - engelska - Ministry of Health

orfadin 10 mg hard capsules

megapharm ltd - nitisinone - hard capsule - nitisinone 10 mg - nitisinone - nitisinone - treatment of patients with confirmed diagnosis of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine05/06/2018 בקשה לשינוי משטר מינון once daily